Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 4 years ago

Possible Interaction: Glucose and Vildagliptin

supplement:

Glucose

Research Papers that Mention the Interaction

To further elucidate these findings, the authors show that the insulin secretory response to glucose is enhanced with vildagliptin treatment not only by oral load but also after iv load, contributing to the numerical similarity of the calculated incretin effects.
The Journal of clinical endocrinology and metabolism  •  2011  |  View Paper
Vildagliptin also significantly decreased the standard deviation of the mean glucose (SD) and the mean of the daily differences (MODD) (p = 0.007 and 0.030).
Diabetes research and clinical practice  •  2018  |  View Paper
There were significant interactions between the rate of ID glucose and VILD treatment on plasma glucose, intact and total GLP-1, and GIP (P < .05 for each) but not insulin, C-peptide, or glucagon.
The Journal of clinical endocrinology and metabolism  •  2016  |  View Paper
Vildagliptin improves the sensitivity of the alpha cell to glucose in patients with T2DM by enhancing the alpha-cell responsiveness to both suppressive effects of hyperglycaemia and stimulatory effects of hypoglycaemia.
Clinical Pharmacokinetics  •  2012  |  View Paper
Vildagliptin also inhibits hepatic glucose production, mainly through changes in islet hormone secretion, and improves insulin sensitivity, as determined with a variety of methods.
Diabetes, obesity & metabolism  •  2011  |  View Paper
Vildagliptin treatment improves β‐cell sensitivity to glucose , producing increased insulin secretory rate relative to glucose in both postprandial and fasting states.
Diabetes, obesity & metabolism  •  2009  |  View Paper
Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose.
Vascular health and risk management  •  2008  |  View Paper
Vildagliptin is a dipeptidyl peptidase-IV inhibitor, which improves glycaemic control by increasing pancreatic beta cell responsiveness to glucose and suppressing inappropriate glucagon secretion.
Diabetologia  •  2007  |  View Paper
Importantly, when the P/C was expressed in relation to the glucose stimulus (i.e., … fasting glucose and glucose AUC(0-240 min), respectively), the P/C relative to glucose was significantly … with vildagliptin vs. placebo, both in the fasting state (p=0.023) and postprandially (p=0.004).
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme  •  2007  |  View Paper
Moreover, vildagliptin significantly decreased serum levels of glucose and lipids (except high density lipoprotein) together with brain MDA, TNF-α, serum DPP-IV activities and NF-κB/p65 gene expression.
European journal of pharmacology  •  2015  |  View Paper
Show More